Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 2;2016(1):648-649.
doi: 10.1182/asheducation-2016.1.648.

What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?

Maissaa Janbain  1 , Steven Pipe  2
Affiliations
Review

What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?

Maissaa Janbain et al. Hematology Am Soc Hematol Educ Program. .

Abstract

A 10-year-old boy presents with a history of severe hemophilia A and high-titer inhibitor that had failed high-dose immune tolerance induction (ITI) with a recombinant factor VIII (rFVIII) product and a plasma-derived FVIII product. You are asked by his mother whether he should be tried on ITI with an extended half-life product, in particular, consideration of a rFVIIIFc concentrate.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.J. has consulted for Bayer Pharmaceuticals and Baxalta Pharmaceuticals. S.P. is on the Board of Directors or an advisory committee for the American Thrombosis and Hemostasis Network, the Medical and Scientific Advisory Council, and the National Hemophilia Foundation, and has consulted for Baxalta, Novo Nordisk, CSL Behring, Biogen, Bayer, and Genentech/Roche.

References

    1. Kasper CK. Diagnosis and management of inhibitors to factors VIII and IX. An introductory discussion for physicians. Montréal, Québec: World Federation of Hemophilia, September 2004. Treatment of Hemophilia Monograph Series. No. 34. Available at: http://www1.wfh.org/publication/files/pdf-1178.pdf. Accessed 27 September 2016.
    1. Oldenburg J, Austin SK, Kessler CM. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective. Haemophilia. 2014;20(suppl 6):17-26. - PubMed
    1. Minno GD, Santagostino E, Pratt K, Königs C. New predictive approaches for ITI treatment. Haemophilia. 2014;20(suppl 6):27-43. - PubMed
    1. Ing M, Gupta N, Teyssandier M, et al. ; ABIRISK Consortium. Immunogenicity of long-lasting recombinant factor VIII products. Cell Immunol. 2016;301:40-48. - PubMed
    1. van Velzen AS, Peters M, van der Bom JG, Fijnvandraat K. Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review. Br J Haematol. 2014;166(4):485-495. - PubMed